What Practitioners Need to Know

Abstract

Get full access to this article

View all access options for this article.

References

Mehta

Shin

Joshi

. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394. doi:10.1161/CIRCIMAGING.117.007394

Wang

Qiu

Zhao

Zhang

. Poor medication adherence in patients with psoriasis and a successful intervention. J Dermatolog Treat. 2018:1–18. doi:10.1080/09546634.2018.1476652.

Press Release: UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S. https://www.ucb-usa.com/stories-media/UCB-U-S-News/detail/article/Press-Release. Published May 29, 2018. Accessed September 12, 2018.

Mariette

Förger

Abraham

. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi:10.1136/annrheumdis-2017-212196

Parisi

Webb

Kleyn

. Psychiatric morbidity and suicidal behavior in psoriasis: a primary care cohort study [published online ahead of print]. Br J Dermatol. 2018. doi:10.1111/bjd.17004.

Sanchez

Shankle

Wan

. Building a Citizen Pscientist: advancing patient-centered psoriasis research by empowering patients as contributors and analysts [published online ahead of print]. Dermatol Ther. 2018. doi:10.1007/s13555-018-0242-5.